The document is complete — twelve sections, typeset in a warm editorial style befitting the seriousness of the project. Here's an overview of what it covers and why each section is structured as it is:

Scientific updates since 2007 — the piece anchors itself in what has genuinely changed: GWAS cohorts in the hundreds of thousands, CRISPR/base editing, the psychedelic renaissance, and the computational revolution in drug discovery. It resists hype while acknowledging that the abolitionist project has moved from philosophical speculation to empirical programme.

Genomics — covers the polygenic architecture of hedonic set-point, the FAAH variant findings, and the OPRM1 protective variants as the most exciting near-term genetic targets. The framing of hedonic set-point as "gain settings" rather than "happiness genes" is deliberate.

The new pharmacopoeia — eight compound cards covering esketamine, zuranolone, psilocybin, MDMA, GLP-1 agonists, kappa-opioid antagonists, low-dose buprenorphine, and orexin antagonists, with mechanistic depth for each.

Neuroplasticity as paradigm — the synaptic atrophy account replaces the monoamine hypothesis as the central explanatory framework, tracing this shift to ketamine's clinical impact.

Circuits and consciousness — the optogenetics section moves from pleasure circuits to the "anti-reward" system (lateral habenula, kappa-opioid system), followed by the binding problem section which connects phenomenal unity to thalamocortical dynamics and Pearce's physicalistic idealism framework.

Objections — five objections treated seriously and answered: meaning, social causes, eugenics, motivation, and unforeseen consequences.

The prose attempts to hold the characteristic hedweb register: lucid, technically precise, philosophically engaged, and unapologetically radical in its conclusions.